Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine

OBI Pharma (4174.TWO) announced that it has entered into an exclusive global license agreement with TegMine Therapeutics, Inc. (TegMine), a US-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycoprotein-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. This agreement builds on the research collaboration initiated in June 2025 under the ADC-related Master Services Agreement (MSA).  OBI successfully delivered the glycoprotein-targeting ADC candidate requested by TegMine, and the candidate has been evaluated by TegMine as having strong potential for further clinical development.

TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreement. This international licensing collaboration reflects the potential value of products generated using OBI’s Obrion™ ADC technologies. It enhances OBI’s visibility and competitiveness in the global market, and further strengthens the partnership between the two companies.

The licensed ADC candidate is derived from a glycoprotein monoclonal antibody provided by TegMine and was developed into an ADC by OBI using the Obrion™ ADC technology family, including the GlycOBI^® glycan-conjugation technology, the dual-function enzymatic EndoSymeOBI^®, and the highly hydrophilic linker HYPrOBI^®. The ADC candidate generated with this proprietary site-specific glycan conjugation is homogeneous and scalable for manufacturing.

Dr. Heidi Wang, Chief Executive Officer of OBI Pharma, said, “This strategic collaboration leverages the complementary strengths of both organizations. It not only supports the advancement of OBI’s ADC product development but also expands opportunities for strategic partnerships using our innovative ADC technologies such as GlycOBI^®. We look forward to working closely with TegMine to further develop this novel ADC that may benefit patients with urgent medical needs.”

About GlycOBI^®
OBI has developed a unique glycan-based ADC technology (GlycOBI^®), designed in a Plug and Play format that is compatible with any antibodies, linkers, and payloads, and supports various drug–antibody ratios (DAR). Powered by OBI’s proprietary dual-function enzymatic technology EndoSymeOBI^® and its hydrophilic linker technology HYPrOBI^®, GlycOBI^®, a core component of OBI’s Obrion™ ADC technology family, enables the generation of site-specific and homogeneous ADCs with an efficient and scalable process under GMP conditions.
During the conjugation process, GlycOBI^® avoids disrupting the antibody structure and ensures that the resulting ADC retains biophysical characteristics comparable to the native antibody. In addition, OBI’s linker technology improves payload conjugation efficiency and reduces the propensity for aggregation or degradation, further supporting a stable and well-controlled ADC manufacturing process. GlycOBI^® has overcome limitations commonly associated with traditional ADC approaches and has demonstrated improved antitumor activity and stability in various in vivo studies.

About OBI Pharma

OBI Pharma is a clinical-stage global oncology company established in 2002 and headquartered in Taiwan. Together with its subsidiary OBI Pharma USA, Inc., the company is dedicated to developing innovative cancer therapeutics to provide new treatment options for patients with urgent medical needs.

OBI’s research efforts center on novel antibody-drug conjugates (ADC). Through its patented next-generation conjugation technology platform, Obrion™, OBI has established diverse ADC design modalities. The platform integrates proprietary conjugation and linker technologies, including GlycOBI^®, GlycOBI DUO^®, EndoSymeOBI^®, HYPrOBI^®, and the novel cysteine-conjugation technology ThiOBI^®, to advance next-generation ADC solutions. OBI has developed a next-generation suite of ADC programs. These include monospecific ADCs such as OBI-902 (TROP2) and OBI-904 (Nectin-4); a bispecific single-payload ADC, OBI-201 (HER2 x TROP2); and a bispecific dual-payload ADC, OBI-221 (cMET x HER3). To broaden the applicability of the HYPrOBI^® linker technology, OBI has further developed the ThiOBI^® technology to enable irreversible cysteine-based conjugation. In addition to its ADC programs, OBI’s assets include OBI-3424, a first-in-class AKR1C3-targeted small-molecule prodrug that selectively releases a potent DNA-alkylating agent in the presence of the aldo-keto reductase 1C3 enzyme, which is highly expressed in certain tumors. Additional information can be found at www.obipharma.com .

GlycOBI^®, EndoSymeOBI^®, ThiOBI^®, HYPrOBI^®, and GlycOBI DUO^® are registered trademarks of OBI. Obrion™ is a trademark under registration.

About TegMine Therapeutics

TegMine Therapeutics, Inc., founded in 2017 and headquartered in San Francisco, California, is a biotechnology company focused on developing next-generation therapies targeting cancer-associated glycans and glycoproteins. TegMine’s current research programs include innovative modalities such as ADCs, bispecific antibodies, and cell therapies that aim to recognize tumor-associated glycan epitopes that are largely absent from healthy tissues, thereby improving therapeutic effect while minimizing impact on normal cells.
TegMine’s proprietary TegMiner™ technologies enable the discovery and development of antibodies against previously inaccessible cancer-specific glycan epitopes, opening new therapeutic possibilities for patients with high unmet medical needs. Additional information can be found at www.tegminetx.com.